By Editorial Team 
The promise of artificial intelligence in healthcare is undeniable, offering pathways to improved diagnostics, personalized treatment plans, and operational efficiencies. Yet, for AI health platforms seeking to integrate into value-based care (VBC) arrangements, a critical analytical question looms large: why do VBC contracts necessitate multi-year outcomes data, rather than relying on the often-touted results of pilot programs? The answer lies in the fundamental shift VBC demands, a move from fee-for-service volume to demonstrable, sustained patient outcomes and financial performance over time.
The Imperative of Long-Term Clinical Performance in VBC
Value-based care models are designed to reward providers and technology partners for improving patient health and reducing overall healthcare costs. This paradigm mandates a level of evidence far exceeding short-term efficacy. While initial pilot studies can demonstrate a technology’s potential, they rarely capture the full spectrum of real-world variables, patient adherence challenges, or the long-term durability of clinical benefits and cost savings. This is particularly true for AI health solutions, where the dynamic nature of patient populations and healthcare delivery systems can introduce algorithmic drift and necessitate continuous validation. Many AI health companies, despite their innovative approaches, possess relatively short histories, with most having only 2-3 years of operational data. This limited evidence base presents a significant hurdle for VBC contracts. Consider companies like iRhythm Technologies, a pioneer in ambulatory cardiac monitoring, and HeartFlow, which uses AI to create 3D models of coronary arteries from CT scans. Both have invested heavily in clinical evidence, yet the depth and duration of this evidence become paramount when negotiating VBC agreements that span multiple years. The American College of Cardiology (ACC) and the American Heart Association (AHA) through the Journal of the American Heart Association (JAHA) consistently emphasize the need for robust, long-term data to establish clinical utility and guide practice. For digital health platforms focusing on chronic disease management, such as Omada Health and Hinge Health, which target conditions like diabetes and musculoskeletal pain, respectively, or even behavioral health solutions like Noom and Pear Therapeutics (which filed for bankruptcy in 2023 and whose assets were subsequently sold), the requirement for multi-year outcomes data is even more pronounced. These interventions aim to instill lasting behavioral changes and manage chronic conditions over a patient’s lifetime. A 12-week pilot showing initial weight loss or pain reduction, while encouraging, does not guarantee sustained engagement, continued health improvements, or long-term cost reductions. Payers, operating under VBC frameworks, need assurance that the investment in these platforms will yield benefits that endure, preventing costly relapses or disease progression. As Dr. Eric Topol, a leading voice in digital medicine, frequently highlights, the integration of AI into clinical practice must be grounded in rigorous, independently validated evidence. Similarly, Dr. Valentin Fuster, a renowned cardiologist, underscores the importance of long-term studies to truly understand the impact of interventions on cardiovascular health. Their perspectives reinforce the notion that superficial data is insufficient for transformative healthcare decisions. The relationship between clinical effectiveness and financial performance in VBC is direct: sustained clinical improvements are the bedrock of long-term cost savings. Without multi-year data, the financial performance of AI health solutions in a VBC context remains speculative, undermining the very premise of value-based contracting.
Payer Requirements and Regulatory Context for VBC Contracts
The regulatory landscape, particularly driven by the Centers for Medicare & Medicaid Services (CMS) and its innovation center, the Center for Medicare & Medicaid Innovation (CMMI), explicitly favors interventions with demonstrated long-term impact. CMS VBC Rules increasingly demand evidence of sustained outcomes and cost-effectiveness. This means that AI health solutions, to be viable partners in VBC arrangements, must move beyond pilot results and provide compelling data that illustrates their enduring value. The National Committee for Quality Assurance (NCQA), a leading force in healthcare quality measurement, also emphasizes the importance of sustained outcomes for accreditation and quality reporting. Payers, guided by these standards, are therefore compelled to scrutinize the evidence duration provided by AI health companies. A partnership with an AI vendor without multi-year outcomes data carries significant risk for payers, potentially compromising their ability to meet quality metrics and achieve shared savings targets within VBC contracts. NCQA standards for digital health solutions The financial performance of AI health in VBC contracts hinges on its ability to demonstrably reduce healthcare costs over an extended period. This isn’t merely about short-term efficiencies, but about preventing hospitalizations, reducing emergency department visits, optimizing medication adherence, and managing chronic conditions effectively over years. The data point CW6-DP-15, while not fully detailed here, invariably points to the necessity of multi-year data to accurately assess these complex interactions and quantify true savings. Without this longitudinal perspective, the financial projections for AI health in VBC remain speculative, making it challenging for payers to commit to risk-sharing agreements.
The Path Forward: Sustained Evidence for Sustainable Value
For AI health platforms aiming for deep integration into value-based care, the message is clear: the era of relying solely on pilot results for VBC contracts is drawing to a close. The healthcare ecosystem, driven by regulatory bodies like CMS and quality organizations like NCQA, and championed by clinical leaders such as Eric Topol and Valentin Fuster, is demanding a higher standard of evidence. This standard includes multi-year outcomes data that substantiates not just initial efficacy, but sustained clinical performance and demonstrable financial impact. Companies like iRhythm Technologies, HeartFlow, Omada Health, Hinge Health, Noom, and Pear Therapeutics, among others, must continue to prioritize and publish long-term, peer-reviewed studies to solidify their position within the VBC landscape. Payers, in turn, must maintain their rigorous evidence requirements, ensuring that every AI health tool participating in VBC arrangements contributes genuinely and durably to improved patient health and reduced costs. The future of AI health in VBC is not just about innovation, but about proven, long-term value. CMMI guidance on evidence requirements for VBC models Academic paper on the challenges of short-term evidence in digital health
Frequently Asked Questions
Why do VBC contracts require multi-year outcomes data for AI health solutions?
VBC models reward sustained patient outcomes and financial performance over time, moving beyond short-term efficacy. Pilot studies rarely capture real-world variables, patient adherence, or the long-term durability of clinical benefits and cost savings, which are crucial for assessing AI health solutions in a VBC context.
What kind of evidence is needed for AI health platforms in VBC, especially for chronic disease management?
For chronic disease management, multi-year outcomes data is even more critical. This data must demonstrate sustained engagement, continued health improvements, and long-term cost reductions, as short-term pilots do not guarantee lasting behavioral changes or prevent costly relapses over a patient’s lifetime.
How do regulatory bodies and payers view the need for long-term data in VBC for AI health solutions?
Regulatory bodies like CMS and quality organizations like NCQA explicitly favor interventions with demonstrated long-term impact and sustained outcomes. Payers, guided by these standards, require compelling multi-year data from AI health companies to meet quality metrics and achieve shared savings targets within VBC contracts.
What is the relationship between clinical effectiveness and financial performance for AI health in VBC?
The relationship is direct: sustained clinical improvements are the bedrock of long-term cost savings in VBC. Without multi-year data proving sustained clinical effectiveness, the financial performance of AI health solutions remains speculative, making it difficult for payers to commit to risk-sharing agreements.
